参考文献/References:
[1] Mintz GS,Guagliumi G. Intravascular imaging in coronary artery disease[J]. Lancet,2017,390(10096):793-809.
[2] Shlofmitz E,Ali ZA,Maehara A,et al. Intravascular imaging-guided percutaneous coronary intervention:a universal approach for optimization of stent implantation[J]. Circ Cardiovasc Interv,2020,13(12):e008686.
[3] Her AY,Shin ES. Current management of in-stent restenosis[J]. Korean Circ J,2018,48(5):337-349.
[4] Ullrich H,Olschewski M,Münzel T,et al. Coronary in-stent restenosis:predictors and treatment[J]. Dtsch Arztebl Int,2021,118(38):637-644.
[5] Zhang DM,Chen S. In-stent restenosis and a drug-coated balloon:insights from a clinical therapeutic strategy on coronary artery diseases[J]. Cardiol Res Pract,2020,2020:8104939.
[6] Maehara A,Matsumura M,Ali ZA,et al. IVUS-guided versus OCT-guided coronary?stent implantation:a critical appraisal[J]. JACC Cardiovasc Imaging,2017,10(12):1487-1503.
[7] Shlofmitz E,Case BC,Chen Y,et al. Waksman in-stent restenosis classification:a mechanism-based approach to the treatment of restenosis[J]. Cardiovasc Revasc Med,2021,33:62-67.
[8] Shlofmitz E,Iantorno M,Waksman R. Restenosis of drug-eluting stents:a new classification system based on disease mechanism to guide treatment and state-of-the-art review[J]. Circ Cardiovasc Interv,2019,12(8):e007023.
[9] Torrado J,Buckley L,Durán A,et al. Restenosis,stent thrombosis,and bleeding complications:navigating between Scylla?and?Charybdis[J]. J Am Coll Cardiol,2018,71(15):1676-1695.
[10] Waksman R,Iantorno M. Refractory in-stent restenosis:improving outcomes by standardizing our approach[J]. Curr Cardiol Rep,2018,20(12):140.
[11] Aoki J,Tanabe K. Mechanisms of drug-eluting stent restenosis[J]. Cardiovasc Interv Ther,2021,36(1):23-29.
[12] Sakamoto A,Sato Y,Kawakami R,et al. Risk prediction of in-stent restenosis among patients with coronary drug-eluting stents:current clinical approaches and challenges[J]. Expert Rev Cardiovasc Ther,2021,19(9):801-816.
[13] Kajiya T,Yamaguchi H,Takaoka J,et al. In-stent restenosis assessed with frequency domain optical coherence tomography shows smooth coronary arterial healing process in second-generation drug-eluting stents[J]. Singapore Med J,2019,60(1):48-51.
[14] Chavarría J,Suárez de Lezo J,Ojeda S,et al. Restenosis after everolimus-eluting vascular scaffolding. Angiographic and optical coherence tomography characterization[J]. Rev Esp Cardiol(Engl Ed),2017,70(7):543-550.
[15] Jinnouchi H,Kuramitsu S,Shinozaki T,et al. Difference of tissue characteristics between early and late restenosis after second-generation drug-eluting stents implantation—An optical coherence tomography study[J]. Circ J,2017,81(4):450-457.
[16] Song L,Mintz GS,Yin D,et al. Characteristics of early versus late in-stent restenosis in second-generation drug-eluting stents:an optical coherence tomography study[J]. EuroIntervention,2017,13(3):294-302.
[17] Buccheri S,Franchina G,Romano S,et al. Clinical outcomes following intravascular?imaging-guided versus coronary angiography-guided percutaneous coronary intervention with?stent implantation:a?systematic review and Bayesian network meta-analysis of?31?studies and 17,882 patients[J]. JACC Cardiovasc Interv,2017,10(24):2488-2498.
[18] Yin D,Mintz GS,Song L,et al. In-stent restenosis characteristics and repeat stenting underexpansion:insights from optical coherence tomography[J]. EuroIntervention,2020,16(4):e335-e343.
[19] Fujita T,Takeda T,Hano Y,et al. Post-intervention minimal stent area as a predictor of target lesion revascularization after everolimus-eluting stent implantation for in-stent restenosis:a single-center observational study[J]. Coron Artery Dis,2019,30(6):432-439.
[20] Song HG,Kang SJ,Ahn JM,et al. Intravascular ultrasound assessment of optimal stent area to prevent in-stent restenosis after zotarolimus-,everolimus-,and sirolimus-eluting stent implantation[J]. Catheter Cardiovasc Interv,2014,83(6):873-878.
[21] Ali ZA,Maehara A,Généreux P,et al. Optical coherence tomography compared with intravascular ultrasound and with angiography to guide coronary stent implantation(ILUMIEN Ⅲ:OPTIMIZE PCI):a randomised controlled trial[J]. Lancet,2016,388(10060):2618-2628.
[22] Komukai K,Kubo T,Kitabata H,et al. Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography:the EASY-FIT study[J]. J Am Coll Cardiol,2014,64(21):2207-2217.
[23] Puri R,Nicholls SJ,Shao M,et al. Impact of statins on serial coronary calcification during atheroma progression and regression[J]. J Am Coll Cardiol,2015,65(13):1273-1282.
[24] Fujino A,Mintz GS,Matsumura M,et al. A new optical coherence tomography-based calcium scoring system to predict stent underexpansion[J]. EuroIntervention,2018,13(18):e2182-e2189.
[25] Shlofmitz E,Torguson R,Zhang C,et al. Impact of intravascular ultrasound on Outcomes following PErcutaneous coronary interventioN for In-stent Restenosis(iOPEN-ISR study)[J]. Int J Cardiol,2021,340:17-21.
[26] Gao S,Shen J,Mukku VK,et al. Efficacy of drug-eluting balloons for patients with in-stent restenosis:a meta-analysis of 8 randomized controlled trials[J]. Angiology,2016,67(7):612-621.
[27] Xhepa E,Bresha J,Joner M,et al. Clinical outcomes by optical characteristics of neointima and treatment modality in patients with coronary in-stent restenosis[J]. EuroIntervention,2021,17(5):e388-e395.
[28] Lee JH,Kim U,Kim JS,et al. Clinical implication of neointimal burden in in-stent restenosis treated with drug-coated balloon[J]. Catheter Cardiovasc Interv,2021,98(3):493-502.
[29] Goel SS,Dilip Gajulapalli R,Athappan G,et al. Management of drug eluting stent in-stent restenosis:a systematic review and meta-analysis[J]. Catheter Cardiovasc Interv,2016,87(6):1080-1091.
[30] Siontis GC,Stefanini GG,Mavridis D,et al. Percutaneous coronary interventional strategies for treatment of in-stent restenosis:a network meta-analysis[J]. Lancet,2015,386(9994):655-664.
[31] Rivero F,Bastante T,Cuesta J,et al. Treatment of in-stent restenosis with bioresorbable vascular scaffolds:optical coherence tomography insights[J]. Can J Cardiol,2015,31(3):255-259.
[32] Bossard M,Attinger A,Wolfrum M,et al. Bioresorbable scaffold versus drug coated balloon for treatment of in-stent-restenosis—Long-term outcomes of the randomized ABSORB-ISR trial[J]. Eur Heart J,2020,41(suppl_2):ehaa946.2493.
[33] Rawlins J,Talwar S,Green M,et al. Optical coherence tomography following percutaneous coronary intervention with Excimer laser coronary atherectomy[J]. Cardiovasc Revasc Med,2014,15(1):29-34.
[34] Lee T,Shlofmitz RA,Song L,et al. The effectiveness of excimer laser angioplasty to treat coronary in-stent restenosis with peri-stent calcium as assessed by optical coherence tomography[J]. EuroIntervention,2019,15(3):e279-e288.
[35] Hirose S,Ashikaga T,Hatano Y,et al. Treatment of in-stent restenosis with excimer laser coronary angioplasty:benefits over scoring balloon angioplasty alone[J]. Lasers Med Sci,2016,31(8):1691-1696.
[36] Ishihara T,Dohi T,Nakamura D,et al. Impact of in-stent tissue characteristics on excimer laser coronary angioplasty prior to drug-coated balloon treatment[J]. Int J Cardiol,2021,339:28-32.
[37] Kyaw H,Johal G,Gedela M,et al. Is coronary brachytherapy staging a comeback for the treatment of in-stent restenosis?[J]. Curr Cardiol Rep,2021,23(11):156.
[38] Chen Y,Buchanan KD,Chan RC,et al. Combined vascular brachytherapy and stenting for the treatment of in-stent restenosis[J]. Am J Cardiol,2020,125(5):712-719.
相似文献/References:
[1]刘丹丹 李茜楠 王腾玉 田野.锁骨下动脉狭窄的诊治[J].心血管病学进展,2019,(5):786.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.030]
LIU Dandan,LI Qiannan,WAND Tengyu,et al.Diagnosis and Treatment of Subclavian Artery Stenosis[J].Advances in Cardiovascular Diseases,2019,(5):786.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.030]
[2]韩培天 魏晓岩 杜彬彬 张津宁 王文州 郭艳娇 张克成 李春彦 李文慧.心肌缺血时间对STEMI患者急诊PCI术后早期左室舒张功能的影响及相关因素分析[J].心血管病学进展,2020,(6):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
HAN Pei-tian,WEI Xiaoyan,DU Binbin,et al.Effect of Myocardial Ischemia Duration on Early Left Ventricular Diastolic Function in STEMI Patients After Emergency PCI and Analysis of Related Factors[J].Advances in Cardiovascular Diseases,2020,(5):660.[doi:10.16806/j.cnki.issn.1004-3934.2020.06.024]
[3]马越 宋雷 乔树宾.腔内影像学在冠状动脉支架内再狭窄中应用的研究进展[J].心血管病学进展,2021,(3):202.[doi:10.16806/j.cnki.issn.1004-3934.20.03.003]
MA Yue,SONG Lei,QIAO Shubin.Application of Intravascular Imaging in Coronary Artery In-stent Restenosis[J].Advances in Cardiovascular Diseases,2021,(5):202.[doi:10.16806/j.cnki.issn.1004-3934.20.03.003]
[4]贺彩红 荣晶晶 潘宏伟.定量血流分数在急性心肌梗死中的应用进展[J].心血管病学进展,2021,(4):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
HE Caihong,RONG Jingjing,PAN Hongwei.Progress in the Application of Quantitative Flow Ratio in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):347.[doi:10.16806/j.cnki.issn.1004-3934.2021.04.014]
[5]陈佳仑 李树仁.不同策略血栓抽吸对于急性ST段抬高心肌梗死患者的研究进展[J].心血管病学进展,2021,(7):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
CHEN Jialun,LI Shuren.Different Strategies of Thrombus Aspiration in Patients with Acute ST Elevation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2021,(5):593.[doi:10.16806/j.cnki.issn.1004-3934.2021.07.005]
[6]梁晨笛 秦纲.经皮冠状动脉介入诊疗中穿刺路径研究进展[J].心血管病学进展,2022,(3):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
LIANG Chendi,QIN Gang.Puncture Routes in Percutaneous Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(5):232.[doi:10.16806/j.cnki.issn.1004-3934.2022.03.000]
[7]马兴鸿 汪蕾 方纬.核素心肌显像在冠状动脉慢性完全闭塞临床诊疗中的应用价值[J].心血管病学进展,2022,(4):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
MA Xinghong,WANG Lei,FANG Wei.Application Value of Radionuclide Myocardial Imaging In the Clinical Diagnosis And Treatment of Coronary Chronic Total Occlusion[J].Advances in Cardiovascular Diseases,2022,(5):313.[doi:10.16806/j.cnki.issn.1004-3934.2022.04.007]
[8]管翔 王宇 张成糕 周健 张艺 李庆国.经皮心室辅助装置在复杂高危冠状动脉介入治疗中的应用进展[J].心血管病学进展,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
GUAN Xiang,WANG Yu,ZHANG Chenggao,et al.Application Progress of Percutaneous Ventricular Assist Device in Complex High-Risk Coronary Intervention[J].Advances in Cardiovascular Diseases,2022,(5):394.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.003]
[9]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(5):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[10]宋艳华 来春林 杨五小.急性 ST段抬高型心肌梗死患者微血管功能障碍的研究进展[J].心血管病学进展,2022,(6):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
SONG Yanhua,LAI Chunlin,YANG Wuxiao.Microvascular Dysfunction in Patients with Acute ST-Segment?levation Myocardial Infarction[J].Advances in Cardiovascular Diseases,2022,(5):530.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.013]
[11]袁晓航 冯欢欢 高磊.复发性支架内再狭窄的研究进展[J].心血管病学进展,2022,(8):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
YUAN Xiaohang FENG Huanhuan GAO Lei.Recurrent In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(5):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
[12]徐珂 礼兆悦 熊杰 班小芳 涂应锋.残余心血管风险与冠状动脉支架失败关系的研究进展[J].心血管病学进展,2023,(11):961.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.001]
XU Ke,LI Zhaoyue,XIONG Jie,et al.The Relationship Between Residual Cardiovascular Risk and Coronary Stent Failure[J].Advances in Cardiovascular Diseases,2023,(5):961.[doi:10.16806/j.cnki.issn.1004-3934.2023.11.001]